{"disease":{"id":"cd20-positive-b-cell-non-hodgkin-lymphoma","name":"cd20 positive b cell non hodgkin lymphoma"},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"ruxience","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"CD20 positive diffuse large B cell non Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05805943","title":"Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","has_results":false},{"nct_id":"NCT05395533","title":"A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":147,"lead_sponsor_name":"Zhejiang Teruisi Pharmaceutical Inc.","has_results":false},{"nct_id":"NCT00880815","title":"Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01569750","title":"A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT01729806","title":"Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03332121","title":"B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Shanghai Pharmaceuticals Holding Co., Ltd","has_results":false},{"nct_id":"NCT04103905","title":"A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Beijing Mabworks Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT02483000","title":"Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}